DE69935720D1 - Diamino-propanol-verbindungen zur behandlung von ischaemien - Google Patents

Diamino-propanol-verbindungen zur behandlung von ischaemien

Info

Publication number: DE69935720D1
Authority: DE; Germany
Prior art keywords: treatment; ischemas; diamino; galt; propanol compounds
Prior art date: 1998-07-27
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

DE69935720T

Other languages

English (en)

Other versions

DE69935720T2 (de

Inventor

Subroto Chatterjee

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Johns Hopkins University

Original Assignee

Johns Hopkins University

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-07-27

Filing date

1999-07-22

Publication date

2007-05-16

1999-07-22 Application filed by Johns Hopkins University filed Critical Johns Hopkins University

2007-05-16 Application granted granted Critical

2007-05-16 Publication of DE69935720D1 publication Critical patent/DE69935720D1/de

2007-12-27 Publication of DE69935720T2 publication Critical patent/DE69935720T2/de

2019-07-23 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

238000011282 treatment Methods 0.000 title abstract 2
LSRUBRSFDNKORM-UHFFFAOYSA-N 1,1-diaminopropan-1-ol Chemical class CCC(N)(N)O LSRUBRSFDNKORM-UHFFFAOYSA-N 0.000 title 1
DDOVBCWVTOHGCU-QMXMISKISA-N n-[(e,2s,3r)-3-hydroxy-1-[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxynonadec-4-en-2-yl]octadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)\C=C\CCCCCCCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O DDOVBCWVTOHGCU-QMXMISKISA-N 0.000 abstract 3
150000001875 compounds Chemical class 0.000 abstract 2
238000000034 method Methods 0.000 abstract 2
241000124008 Mammalia Species 0.000 abstract 1
HSCJRCZFDFQWRP-ABVWGUQPSA-N UDP-alpha-D-galactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O1 HSCJRCZFDFQWRP-ABVWGUQPSA-N 0.000 abstract 1
WPIHMWBQRSAMDE-YCZTVTEBSA-N beta-D-galactosyl-(1->4)-beta-D-galactosyl-N-(pentacosanoyl)sphingosine Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO[C@@H]1O[C@H](CO)[C@H](O[C@@H]2O[C@H](CO)[C@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O)[C@H](O)\C=C\CCCCCCCCCCCCC WPIHMWBQRSAMDE-YCZTVTEBSA-N 0.000 abstract 1
230000002255 enzymatic effect Effects 0.000 abstract 1
238000000099 in vitro assay Methods 0.000 abstract 1
238000005462 in vivo assay Methods 0.000 abstract 1
238000011321 prophylaxis Methods 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Psychology (AREA)
Marine Sciences & Fisheries (AREA)
Psychiatry (AREA)
Ophthalmology & Optometry (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Saccharide Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

DE69935720T 1998-07-27 1999-07-22 Diamino-propanol-verbindungen zur behandlung von ischaemien Expired - Fee Related DE69935720T2 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US9429898P	1998-07-27	1998-07-27
US94298P		1998-07-27
PCT/US1999/016667 WO2000006145A1 (en)	1998-07-27	1999-07-22	Methods for treating conditions modulated by lactosylceramide

Publications (2)

Publication Number	Publication Date
DE69935720D1 true DE69935720D1 (de)	2007-05-16
DE69935720T2 DE69935720T2 (de)	2007-12-27

Family

ID=22244359

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE69935720T Expired - Fee Related DE69935720T2 (de)	1998-07-27	1999-07-22	Diamino-propanol-verbindungen zur behandlung von ischaemien

Country Status (9)

Country	Link
US (1)	US6511979B1 (de)
EP (1)	EP1098642B1 (de)
JP (1)	JP2002521435A (de)
AT (1)	ATE358473T1 (de)
AU (1)	AU756008B2 (de)
CA (1)	CA2336549A1 (de)
DE (1)	DE69935720T2 (de)
ES (1)	ES2285852T3 (de)
WO (1)	WO2000006145A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6303774B1 (en) *	1999-08-20	2001-10-16	Sri International	Nucleoside pyrophosphate and triphosphate analogs and related compounds
US20040220100A1 (en) *	2000-07-21	2004-11-04	Essentia Biosystems, Inc.	Multi-component biological transport systems
EP1358172B1 (de)	2001-01-10	2009-11-18	The Regents of The University of Michigan	Aminoceramidartige verbindungen und therapeutische anwendungen
EP1370570B1 (de) *	2001-02-28	2007-01-24	John H. Griffin	Plasmaglucosylceramiddefizienz als risikofaktor für thrombose und modulator von anticoagulant protein c
JP4986335B2 (ja) *	2001-05-15	2012-07-25	生化学工業株式会社	Ｖｄａｃ機能阻害剤
ES2399323T3 (es) *	2001-07-16	2013-03-27	Genzyme Corporation	Síntesis de inhibidores de la UDP-glucosa:N-acilesfingosina glucosiltransferasa
CA2464609A1 (en) *	2001-10-26	2003-05-01	University Technologies International, Inc.	Use of egf to inhibit pathogenic infections of the urogenital tract
US6916802B2 (en) *	2002-04-29	2005-07-12	Genzyme Corporation	Amino ceramide-like compounds and therapeutic methods of use
US20060217560A1 (en) *	2002-04-29	2006-09-28	Shayman James A	Amino ceramide-like compounds and therapeutic methods of use
US8500751B2 (en)	2004-03-31	2013-08-06	Merlin Md Pte Ltd	Medical device
SG133420A1 (en) *	2005-12-13	2007-07-30	Merlin Md Pte Ltd	An endovascular device with membrane having permanently attached agents
EP1734897A4 (de)	2004-03-31	2010-12-22	Merlin Md Pte Ltd	Verfahren zur behandlung von aneurysmen
WO2005123055A2 (en) *	2004-06-14	2005-12-29	Musc Foundation For Research Development	Methods for treating inflammatory disorders
WO2006023827A2 (en) *	2004-08-20	2006-03-02	The Johns Hopkins University	Methods for treatment of angiogenesis
WO2006053043A2 (en)	2004-11-10	2006-05-18	Genzyme Corporation	Methods of treating diabetes mellitus
RU2007123604A (ru) *	2004-11-24	2008-12-27	Тэракайн Корпорэйшн (Us)Тэракайн Корпорэйшн (Us)	Имплантат для внутриглазной доставки лекарственных средств
CA2509083A1 (en) *	2004-12-22	2006-06-22	Merlin Md Pte Ltd	A medical device
ES2546181T3 (es)	2006-05-09	2015-09-21	Genzyme Corporation	Métodos de tratar la enfermedad del hígado graso mediante inhibición de la síntesis de glucoesfingolípidos
EP2594564B1 (de)	2007-05-31	2016-09-28	Genzyme Corporation	Glukosylceramid-Synthase-Hemmer vom 2-Acylaminpropanol-Typ
EP2550965B1 (de)	2007-10-05	2019-01-16	Genzyme Corporation	Ceramidderivate zur Behandlung polyzystischer Nierenerkrankung
WO2010014554A1 (en)	2008-07-28	2010-02-04	Genzyme Corporation	Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
MX2011003517A (es) *	2008-10-03	2011-05-25	Genzyme Corp	Inhibidores de la glucosilceramida sintasa tipo 2-acilaminopropanol.
NZ625712A (en)	2009-11-27	2016-02-26	Genzyme Corp	An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase
WO2011099980A1 (en)	2010-02-12	2011-08-18	The Johns Hopkins University	Use of the lactosylceramide synthase isoform b1, 4galt-v as a biomarker for cancer
ES2943709T3 (es)	2012-04-06	2023-06-15	Merlin Md Pte Ltd	Dispositivos para tratar un aneurisma

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5041441A (en)	1988-04-04	1991-08-20	The Regents Of The University Of Michigan	Method of chemotherapy using 1-phenyl-2-decanoylamino-3-morpholino-1-propanol
US5302609A (en)	1992-12-16	1994-04-12	The Regents Of The University Of Michigan	Treatment of diabetic nephropathy
US5399567A (en)	1993-05-13	1995-03-21	Monsanto Company	Method of treating cholera
US5339567A (en)	1993-06-22	1994-08-23	Pierpont John M	Interior-mounted security bars
KR960703598A (ko)	1993-08-13	1996-08-31	와따루 야마야	신경 질환 치료제(agent for curing neurotic diseases)
CN1152907A (zh) *	1994-06-10	1997-06-25	生化学工业株式会社	2-酰胺基丙醇化合物及其药物组合物
US5972928A (en) *	1997-05-21	1999-10-26	Johns Hopkins University	Methods for treatment of conditions associated with lactosylceramide

1999
- 1999-07-22 JP JP2000562000A patent/JP2002521435A/ja not_active Withdrawn
- 1999-07-22 DE DE69935720T patent/DE69935720T2/de not_active Expired - Fee Related
- 1999-07-22 AT AT99937409T patent/ATE358473T1/de not_active IP Right Cessation
- 1999-07-22 WO PCT/US1999/016667 patent/WO2000006145A1/en active IP Right Grant
- 1999-07-22 US US09/359,023 patent/US6511979B1/en not_active Expired - Fee Related
- 1999-07-22 AU AU52249/99A patent/AU756008B2/en not_active Ceased
- 1999-07-22 ES ES99937409T patent/ES2285852T3/es not_active Expired - Lifetime
- 1999-07-22 CA CA002336549A patent/CA2336549A1/en not_active Abandoned
- 1999-07-22 EP EP99937409A patent/EP1098642B1/de not_active Expired - Lifetime

Also Published As

Publication number	Publication date
EP1098642B1 (de)	2007-04-04
ES2285852T3 (es)	2007-11-16
DE69935720T2 (de)	2007-12-27
EP1098642A1 (de)	2001-05-16
ATE358473T1 (de)	2007-04-15
JP2002521435A (ja)	2002-07-16
AU5224999A (en)	2000-02-21
CA2336549A1 (en)	2000-02-10
US6511979B1 (en)	2003-01-28
WO2000006145A1 (en)	2000-02-10
EP1098642A4 (de)	2004-08-18
AU756008B2 (en)	2003-01-02

Publication	Publication Date	Title
DE69935720D1 (de)	2007-05-16	Diamino-propanol-verbindungen zur behandlung von ischaemien
TW200505901A (en)	2005-02-16	Muscarinic agonists
UA70958C2 (uk)	2004-11-15	Спосіб лікування захворювання, пов'язаного з порушенням метаболізму естрогену (варіанти)
EA200101166A1 (ru)	2002-06-27	Ингибиторы металлопротеаз
DE69941429D1 (de)	2009-10-29	1-deoxy-galactonojirimycin-derivate zur vewendung bei der behandlung von lysosomalen speicherkrankheiten mittels steigerung der lysosomalen alpha galactosidase a
MX9606386A (es)	1997-03-29	Agentes que afectan la hemostasis trombotica.
CY1107495T1 (el)	2013-03-13	Χρηση παραγωγων τετρακυκλινης για να αυξανεται παραγωγη ιντepλευκινης-10
FI961976A0 (fi)	1996-05-09	Peptidyyliyhdisteitä ja niiden terapeuttinen käyttö metalloproteinaasien inhibiittoreina
DE69329856D1 (de)	2001-02-15	Ester derivate von 4-aza-steroiden
BRPI0411319A (pt)	2006-07-18	compostos terapeuticamente ativos e sua utilização
NO985232L (no)	1998-12-04	Androstenderivater
ATE239709T1 (de)	2003-05-15	Racemisches huperzin a
ATE201597T1 (de)	2001-06-15	Verabreichung von riluzol zur behandlung von neuro-aids
BR0013935A (pt)	2002-05-14	IsÈmeros oticamente ativos de cetotifeno e metabólitos terapeuticamente ativos dos mesmos
AU7934900A (en)	2001-04-30	Method of screening for inhibitors of asp2
BR0012696A (pt)	2002-04-09	Composição oftálmica
DE69725882D1 (de)	2003-12-04	Adenovirus e4 proteine für induktion von zelltod
ATE271861T1 (de)	2004-08-15	Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
TR200101245T2 (tr)	2001-10-22	N-arilsulfonil-aminoasit-omega-amidler
ES2099747T3 (es)	1997-06-01	Aplicacion topica terapeuticamente eficaz de la st1435.
MXPA02004702A (es)	2004-09-10	Analogos interrumpidos por heteroatomos de acido 15-hidroxieicosatetraenoico y metodos de uso.
DE69727583D1 (de)	2004-03-18	Vermeidung von gastrointestinaler schädigung
MXPA02004699A (es)	2004-09-10	Derivados de acidos hidroxieicosatetraenoico modificados con cadena omega y metodos de su uso para el tratameinto del ojo reseco.
ATE252903T1 (de)	2003-11-15	Arzneimittel zur behandlung konvulsivischer zustände
BR0012121A (pt)	2002-05-14	Derivado de aminotetralina para terapia de doenças cardiovasculares

Legal Events

Date	Code	Title	Description
2008-04-24	8364	No opposition during term of opposition
2010-05-20	8339	Ceased/non-payment of the annual fee